Latest Asx Compliance News

Vintage Energy has addressed an ASX compliance issue related to the timing of its May 2025 securities issuance, confirming reliance on its placement capacities to maintain regulatory adherence.

Openn Negotiation Ltd reported a significantly reduced net loss of $3.93 million for FY24, exiting voluntary administration with new directors and a recapitalisation led by ST Holding 2 Pty Ltd. The company faces challenges in regaining ASX compliance and identifying new business operations.

Scalare Partners Holdings Limited has had its trading suspension lifted following its announcement of a capital raising to fund the acquisition of Tank Stream Labs.

Australian Rare Earths (ASX, AR3) has responded to an ASX price query, denying any undisclosed price-sensitive information and attributing recent trading activity to sector interest and recent company announcements.

Lumos Diagnostics Holdings Limited has had its ASX trading suspension lifted following news of a strategic material agreement, signaling potential growth ahead.

Scalare Partners Holdings has voluntarily suspended trading on the ASX as it prepares to announce a capital raising tied to its planned acquisition of Tank Stream Labs.

Pact Group Holdings Ltd has requested suspension of its shares from ASX trading as it prepares for removal from the official list, signaling a major shift for investors.

Advanced Health Intelligence has been formally delisted from NASDAQ due to shareholder equity deficiencies but is actively pursuing ASX reinstatement as a critical step toward regaining its dual-listing status.

Bowen Coking Coal Limited has had its ASX trading suspension lifted following its disclosure on funding efforts amid challenging market conditions. The company confirmed compliance with ASX rules, paving the way for immediate reinstatement.

Trigg Minerals has withdrawn previously reported mineral resource estimates for its Antimony Canyon Project after ASX compliance review, while reaffirming confidence in ongoing exploration efforts.

Alterity Therapeutics has responded to an ASX inquiry about its recent share price and volume spike, confirming no undisclosed information but highlighting imminent clinical data releases and investor roadshows as possible drivers.

Invion Limited’s IVXO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing and investor confidence.